The struggling biotech Verastem that has seen its stock nose-dive will look to a future without executive chairman Christoph Westphal and director Henri Termeer.
After a slew of failures in mesothelioma, there has been a small bright spot today after the FDA accepted an IND for Epizyme’s experimental treatment for the hard-to-treat cancer.